Search Results

Return to List
Results 1–4 of 4
Title Date
1.

Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period

Number 623

(Replaces Committee Opinion Number 514, December 2011)

ABSTRACT: Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur in pregnant women or women in the postpartum period. Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrat...

February 2015

PDF Format
2.

Magnesium Sulfate Use in Obstetrics

Number 573

ABSTRACT: The U.S. Food and Drug Administration advises against the use of magnesium sulfate injections for more than 5–7 days to stop preterm labor in pregnant women. Based on this, the drug classification was changed from Category A to Category D, and the labeling was changed to include this new...

September 2013

PDF Format
3.

Compounded Bioidentical Menopausal Hormone Therapy

Number 532

(Reaffirmed 2014, Replaces No. 387, November 2007 and No. 322, November 2005)

ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall effectiveness, has reinforced its usefulness for short-term treatment of menopausal symptoms. Meno...

August 2012

PDF Format
4.

Subclinical Hypothyroidism in Pregnancy

Number 381

(Reaffirmed 2012)

ABSTRACT: Subclinical hypothyroidism is diagnosed in asymptomatic women when the thyroid-stimulating hormone level is elevated and the free thyroxine level is within the reference range. Thyroid hormones, specifically thyroxine, are essential for normal fetal brain development. However, data indic...

October 2007

PDF Format

American Congress of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188 | Mailing Address: PO Box 70620, Washington, DC 20024-9998